Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 11, 2003

View Archived Issues

Business highlights at Regeneron

Scancell and Celltech collaborate on antibody therapeutics to Lewis(y/b)

Levitra is effective in men of diverse ethnic origin

New NHE-3 inhibitors and their use covered by Merck KGaA patent

Merck KGaA presents novel PDE7 inhibitors

New PARP inhibitors in early development at Fujisawa

Dual 5-HT/noradrenaline uptake inhibitors and their use described by Lundbeck

MMP inhibitors, their preparation and biological evaluation reported by Sumitomo

Micrologix claims new L-nucleoside derivatives with anti-HBV activity

EP2 receptor agonist CP-533536 offers a therapeutic alternative for bone fractures and defects

E.U. orphan drug status awarded to Fidelin for adrenal insufficiency

Pivotal phase III trial for Cellegesic makes solid progress

CART-2 trial of AGI-1067 completes enrollment

Lapdap approved by U.K. agency for treatment of P. falciparum malaria

EFECT studies new breast cancer population for Faslodex

Quark Biotech and Fujisawa extend stroke collaboration

ACP-103 completes phase I testing

FDA panel recommends Onyx for treatment of arteriovenous malformations

Phase III study for RSD-1235 in atrial fibrillation commences dosing

Combination of NF-kB inhibitors and DNA-damaging agents for improving therapeutic outcome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...